WHO ICTRP trial
A study to determine the safety, tolerability and effects of orally administered…
ACTRN12611000472976 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12611000472976 |
|---|---|
| Public title | A study to determine the safety, tolerability and effects of orally administered 3,5-diiodothyropropionic acid (DITPA) in patients with Allan-Herndon-Dudley-Syndrome (AHDS). |
| Scientific title | A multi-centre, open-label study to determine the safety, tolerability and pharmacodynamics of orally administered 3,5-diiodothyropropionic acid (DITPA) in patients aged 3 to 12 with Allan-Herndon-Dudley Syndrome (AHDS) |
| Primary sponsor | Zarion Pharmaceuticals |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 0 |
| Countries | Australia |
| Conditions | Allan-Herndon-Dudley Syndrome (AHDS); Allan-Herndon-Dudley Syndrome (AHDS);Human Genetics and Inherited Disorders - Other human genetics and inherited disorders |
| Interventions | 3,5-diiodothyropropionic Acid (DITPA) will be administered daily started at a dose of 1.5 mg/kg/d and increased to 4.75 mg/kg/d. The dose may be escalated from 1.5 mg/kg/d in increments of 33%, at the discretion of the treating physician… |
| Registration date | Jun 5, 2011 |
| Target size | 10 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: